8-K: Neuronetics Reports Strong Q2 2026 Results, Improved Profitability

Neuronetics, Inc. announced its second quarter 2026 financial and operating results, highlighting a 9.1% increase in total revenue and a significant reduction in net loss.

Summary

• Neuronetics reported total revenue of $41.6 million for Q2 2026, a 9.1% increase year-over-year.
• Greenbrook revenue grew by 16.8% to $26.9 million.
• Adjusted EBITDA improved to $0.3 million, a substantial increase from a loss of $5.6 million in Q2 2025.
• Net loss decreased to $3.4 million ($0.05 per share) from $10.1 million ($0.15 per share) in Q2 2025.
• Net cash used in operations and investing was reduced to $1.4 million, down from $3.8 million in Q2 2025.
• The company strengthened its leadership team with key appointments in finance and sales.
• Full-year 2026 revenue guidance is projected between $160 million and $164 million.
• Full-year 2026 gross margin guidance is revised upwards to 48%-50%.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with the company showing significant improvements in financial metrics and strategic leadership, indicating a stronger operational trajectory.

Positives

• Total revenue increased by 9.1% to $41.6 million in Q2 2026.
• Greenbrook revenue showed strong growth of 16.8% to $26.9 million.
• Adjusted EBITDA turned positive at $0.3 million, a significant improvement from a $5.6 million loss in the prior year.
• Net loss was reduced by $6.7 million to $3.4 million.
• Operating expenses decreased by 12% to $22.7 million due to lower G&A and S&M expenses.
• Gross margin improved to 51.1% from 46.6% in Q2 2025.
• Net cash used in operations and investing decreased by $2.3 million.
• Strengthened leadership team with experienced professionals in key roles.

Negatives

• The company continues to report a net loss, albeit significantly reduced.
• Total cash decreased from $34.1 million at the end of 2025 to $25 million as of June 30, 2026.

Risks

• Ability to achieve or sustain profitable operations due to a history of losses.
• Reliance on the sale and usage of the NeuroStar Advanced Therapy System for revenue.
• Availability of coverage and reimbursement from third-party payors.
• Physician and patient demand for treatments.
• Developments in competing technologies and therapies.
• Potential effects of evolving and/or extensive government regulation.
• Ability to achieve positive cash flows and continue as a going concern.

Future Outlook

For the full year 2026, Neuronetics expects total revenue between $160 million and $164 million, gross margin between 48% and 50%, and operating expenses between $95 million to $100 million (excluding stock-based compensation). Cash flow from operations and investing is projected to be in the range of negative $10.5 million to negative $14.5 million.

Management Comments

• "This was a quarter of real operational progress, and meaningful steps toward our goal of sustained profitability and positive net cash flow from operations and investing," said Dan Reuvers, President and Chief Executive Officer of Neuronetics.
• "For some time, NeuroStar has not competed to its full potential, and we are changing that by broadening how customers can access our technology while we continue to drive operational gains across the Greenbrook clinics."
• "We also strengthened our leadership team, adding proven talent in key roles."
• "The combination of a leading TMS platform and a national care network is what sets Neuronetics apart, and it positions us to lead as new interventional therapies come to market."
• "There is more work ahead, but I am encouraged by the traction we are beginning to demonstrate."

Industry Context

StockSavvy.ai notes that Neuronetics' results reflect a positive trend in the interventional mental health sector, particularly with the growth of its integrated model combining TMS technology and direct patient care through Greenbrook. The company's strategic shift in its go-to-market approach for NeuroStar, offering capital purchase, leasing, and session-based models, is a key initiative to broaden market access and capture a larger share in a competitive landscape.

Management Changes

Stakeholder Impact

• Shareholders: Improved financial performance and positive operational trends may lead to increased investor confidence.
• Employees: Leadership changes and strategic focus could signal opportunities for growth and development within the company.
• Customers (Clinics/Physicians): The new go-to-market strategies for NeuroStar aim to provide more flexible access options, potentially benefiting a wider range of customers.
• Patients: Continued focus on interventional mental health therapies and expanded access to NeuroStar and Greenbrook services could benefit patients seeking treatment.

Next Steps

• Continue to drive operational gains across Greenbrook clinics.
• Broaden customer access to NeuroStar technology through new go-to-market models.
• Leverage the combined strengths of the NeuroStar platform and Greenbrook network.
• Position the company to lead as new interventional therapies enter the market.

Key Dates

Recommendation

The company is showing significant operational improvements and a positive trend towards profitability, with revenue growth and reduced losses. However, it continues to operate at a net loss and has a history of losses, indicating ongoing risks. The strategic shifts in go-to-market strategy are promising but require time to demonstrate sustained financial success. Therefore, a 'hold' recommendation is appropriate, pending further evidence of sustained profitability and positive cash flow.

Keywords

Neuronetics, NeuroStar TMS, Greenbrook, Mental Health, Depression Treatment, TMS Therapy, Financial Results, Q2 2026